Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Repligen (RGEN) and Travere Therapeutics (TVTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on MannKind (MNKD – Research Report), Repligen (RGEN – Research Report) and Travere Therapeutics (TVTX – Research Report) with bullish sentiments.

MannKind (MNKD)

In a report issued on September 20, Thomas Smith from SVB Securities reiterated a Buy rating on MannKind. The company’s shares closed last Thursday at $3.17.

According to TipRanks.com, Smith has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -13.1% and a 32.3% success rate. Smith covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Connect Biopharma Holdings, and Madrigal Pharmaceuticals.

Currently, the analyst consensus on MannKind is a Moderate Buy with an average price target of $5.00.

See the top stocks recommended by analysts >>

Repligen (RGEN)

SVB Securities analyst Puneet Souda maintained a Buy rating on Repligen on September 21 and set a price target of $250.00. The company’s shares closed last Thursday at $189.94.

According to TipRanks.com, Souda has 0 stars on 0-5 stars ranking scale with an average return of -11.9% and a 33.9% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Repligen with a $267.00 average price target.

Travere Therapeutics (TVTX)

SVB Securities analyst Joseph Schwartz maintained a Buy rating on Travere Therapeutics on September 20 and set a price target of $45.00. The company’s shares closed last Thursday at $24.73.

According to TipRanks.com, Schwartz is ranked 0 out of 5 stars with an average return of -11.4% and a 39.1% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Crinetics Pharmaceuticals.

Currently, the analyst consensus on Travere Therapeutics is a Strong Buy with an average price target of $41.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MNKD:

• Analysts Have Conflicting Sentiments on These Technology Companies: Cognex (CGNX), Omnicell (OMCL) and Sprout Social (SPT)
• Analysts Conflicted on These Industrial Goods Names: Acuity Brands (AYI) and Verra Mobility (VRRM)
• Salesforce (CRM): New Buy Recommendation for This Technology Giant
• PagerDuty (PD) Gets a Buy from Robert W. Baird
• Robert W. Baird Remains a Hold on Columbia Sportswear (COLM)